Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Statin Responses in Chinese Patients.

× No keyword cloud information.

13 in total

1. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?

Authors: Bruce K Birmingham; Sarah R Bujac; Robert Elsby; Connie T Azumaya; Cheryl Wei; Yusong Chen; Rogelio Mosqueda-Garcia; Helen J Ambrose
Journal: Eur J Clin Pharmacol Date: 2015-02-12 Impact factor: 2.953

2. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.

Authors: Edmund Lee; Stephen Ryan; Bruce Birmingham; Julie Zalikowski; Ruth March; Helen Ambrose; Rachael Moore; Caroline Lee; Yusong Chen; Dennis Schneck
Journal: Clin Pharmacol Ther Date: 2005-10 Impact factor: 6.875

Review 3. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.

Authors: Michael H Davidson
Journal: Expert Opin Drug Saf Date: 2004-11 Impact factor: 4.250

4. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.

Authors: Paul D Martin; Mike J Warwick; Aaron L Dane; Mireille V Cantarini
Journal: Clin Ther Date: 2003-08 Impact factor: 3.393

5. Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments.

Authors: Kenneth K W To; Miao Hu; Brian Tomlinson
Journal: Pharmacogenomics Date: 2014-06 Impact factor: 2.533

6. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

Authors: Marianne K DeGorter; Rommel G Tirona; Ute I Schwarz; Yun-Hee Choi; George K Dresser; Neville Suskin; Kathryn Myers; GuangYong Zou; Otito Iwuchukwu; Wei-Qi Wei; Russell A Wilke; Robert A Hegele; Richard B Kim
Journal: Circ Cardiovasc Genet Date: 2013-07-22

7. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

Authors: Daniel I Chasman; Franco Giulianini; Jean MacFadyen; Bryan J Barratt; Fredrik Nyberg; Paul M Ridker
Journal: Circ Cardiovasc Genet Date: 2012-02-13

8. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.

Authors: Hon-Kit Lee; Miao Hu; Sandra Sh Lui; Chung-Shun Ho; Chun-Kwok Wong; Brian Tomlinson
Journal: Pharmacogenomics Date: 2013-08 Impact factor: 2.533

Review 9. Racial Differences in the Cholesterol-Lowering Effect of Statin.

Authors: Ryo Naito; Katsumi Miyauchi; Hiroyuki Daida
Journal: J Atheroscler Thromb Date: 2016-10-12 Impact factor: 4.928

10. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

Authors:
Journal: Eur Heart J Date: 2013-02-26 Impact factor: 29.983

9 in total

1. Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults.

Authors: Raju Kanukula; Abdul Salam; Anthony Rodgers; Bishoy Kamel
Journal: Clin Pharmacokinet Date: 2021-01-11 Impact factor: 6.447

Review 2. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419

Review 3. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors: Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal: Int J Mol Sci Date: 2021-12-10 Impact factor: 5.923

4. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial.

Authors: Yundai Chen; Zuyi Yuan; Juming Lu; Freddy G Eliaschewitz; Alberto J Lorenzatti; Maria Laura Monsalvo; Nan Wang; Andrew W Hamer; Junbo Ge
Journal: Diabetes Obes Metab Date: 2019-04-14 Impact factor: 6.577

5. Descriptive analysis of real-world medication use pattern of statins and antiplatelet agents among patients with acute coronary syndrome in Hong Kong and the USA.

Authors: Yun Wang; Michael B Nichol; Bryan Py Yan; Joanne Wu; Brian Tomlinson; Vivian Wy Lee
Journal: BMJ Open Date: 2019-07-16 Impact factor: 2.692

6. Statin Intolerance-An Asian Perspective.

Authors: Brian Tomlinson; Paul Chan; Zhong-Min Liu
Journal: J Atheroscler Thromb Date: 2019-09-25 Impact factor: 4.928

7. Evaluation of small dense low-density lipoprotein concentration for predicting the risk of acute coronary syndrome in Chinese population.

Authors: Bin Wu; Zhiwu Yu; Tong Tong; Xinxin Tong; Yinmei Yang; Yongcai Tang; Huiming Ren; Yike Liao; Jun Liao
Journal: J Clin Lab Anal Date: 2019-11-07 Impact factor: 2.352

8. Intensive vs non-intensive statin pretreatment before percutaneous coronary intervention in Chinese patients: A meta-analysis of randomized controlled trials.

Authors: Xian Yang; Xi Lan; Xin-Lin Zhang; Zhong-Lin Han; Si-Min Yan; Wen-Xiao Wang; Biao Xu; Wei-Hong Ge
Journal: World J Clin Cases Date: 2022-02-16 Impact factor: 1.337

9. Clinical and Economic Analysis of Lipid Goal Attainments in Chinese Patients with Acute Coronary Syndrome Who Received Post-Percutaneous Coronary Intervention.

Authors: Yun Wang; Bryan Ping Yen Yan; Brian Tomlinson; Michael Bruce Nichol; Vivian Wing Yan Lee
Journal: J Atheroscler Thromb Date: 2018-06-29 Impact factor: 4.928

9 in total